Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial

RCT (n=242) found that the risk of developing a second seizure during 24-weeks treatment was lower with lacosamide than placebo (HR 0.54, 95%CI 0.38-0.77). Median time to 2nd seizure was 77 days for placebo, vs not achieved with lacosamdie (<50% had a seizure by study endpoint).


Journal of Neurology Neurosurgery and Psychiatry